The company operates as an intellectual property and technology licensing model, leveraging strategic partnerships with major research institutions including MD Anderson Cancer Center and University of New Mexico Health Sciences Center. Manhattan Scientifics holds significant equity stakes in spinoff companies and derives value primarily through technology transfer and commercialization rather than direct operations.
Cyborg Score Rationale
The company faces substantial operational and financial headwinds despite holding promising early-stage technologies. With a market cap of $55.9K (as of February 2026) and minimal publicly disclosed revenue, combined with the highly speculative nature of nanomedicine development and intense competition from well-capitalized biotech firms, execution risks are extremely high.
Top Insights
Primary asset is majority stake in Imagion Biosystems Ltd (50M+ shares), an ASX-listed cancer diagnostic company with proprietary nanomagnetic detection technology for early cancer detection
Acquired Metallicum Inc. and nanostructured metals technology from Los Alamos National Laboratory, enabling lighter, stronger metal alloys for medical prosthetics and industrial applications
Operates on a licensing model rather than direct product development, reducing operational burden but creating dependency on partner commercialization success
Minimal disclosed revenue and market capitalization under $56K indicates extreme liquidity constraints and limited ability to fund development or marketing independently
Named Competitors
Imagion Biosystems Ltd — ASX-listed cancer diagnostic company using nanomagnetic detection technology
Guardant Health — Liquid biopsy and cancer diagnostics
Foundation Medicine — Genomic cancer diagnostics and precision oncology
Recent Developments
(February 2021) Announced positive early results from Imagion Biosystems cancer diagnostic human study; Imagion shares traded up 46% on 71M share volume
(February 2026) Market capitalization reported at $55.9K with 559.28M shares outstanding, reflecting severe capital constraints
Open the full interactive Manhattan Scientifics Inc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.